- Home
- EVV vs SNDX Comparison
EVV vs SNDX Comparison
Compare EVV & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVV
- SNDX
- Stock Information
- Founded
- EVV 2003
- SNDX 2005
- Country
- EVV United States
- SNDX United States
- Employees
- EVV N/A
- SNDX N/A
- Industry
- EVV Finance/Investors Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- EVV Finance
- SNDX Health Care
- Exchange
- EVV Nasdaq
- SNDX Nasdaq
- Market Cap
- EVV 1.2B
- SNDX 1.1B
- IPO Year
- EVV N/A
- SNDX 2016
- Fundamental
- Price
- EVV $10.23
- SNDX $15.04
- Analyst Decision
- EVV
- SNDX Strong Buy
- Analyst Count
- EVV 0
- SNDX 10
- Target Price
- EVV N/A
- SNDX $38.40
- AVG Volume (30 Days)
- EVV 323.7K
- SNDX 2.0M
- Earning Date
- EVV 01-01-0001
- SNDX 11-04-2025
- Dividend Yield
- EVV 9.66%
- SNDX N/A
- EPS Growth
- EVV N/A
- SNDX N/A
- EPS
- EVV N/A
- SNDX N/A
- Revenue
- EVV N/A
- SNDX $77,933,000.00
- Revenue This Year
- EVV N/A
- SNDX $585.73
- Revenue Next Year
- EVV N/A
- SNDX $94.17
- P/E Ratio
- EVV N/A
- SNDX N/A
- Revenue Growth
- EVV N/A
- SNDX 2126.66
- 52 Week Low
- EVV $8.52
- SNDX $8.58
- 52 Week High
- EVV $10.07
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- EVV 51.75
- SNDX 49.91
- Support Level
- EVV N/A
- SNDX $15.71
- Resistance Level
- EVV $10.41
- SNDX $16.50
- Average True Range (ATR)
- EVV 0.06
- SNDX 0.82
- MACD
- EVV -0.39
- SNDX -0.31
- Stochastic Oscillator
- EVV 98.22
- SNDX 2.44
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.